Neprilysin inhibition in chronic kidney disease.
Despite current practice, patients with chronic kidney disease (CKD) are at increased risk of progression to end-stage renal disease and cardiovascular events. Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. NEPi enhances the activ...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1826297928431435776 |
|---|---|
| author | Judge, P Haynes, R Landray, M Baigent, C |
| author_facet | Judge, P Haynes, R Landray, M Baigent, C |
| author_sort | Judge, P |
| collection | OXFORD |
| description | Despite current practice, patients with chronic kidney disease (CKD) are at increased risk of progression to end-stage renal disease and cardiovascular events. Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. NEPi enhances the activity of natriuretic peptide systems leading to natriuresis, diuresis and inhibition of the renin-angiotensin system (RAS), which could act as a potentially beneficial counter-regulatory system in states of RAS activation such as chronic heart failure (HF) and CKD. Early NEPi drugs were combined with angiotensin-converting enzyme inhibitors but were associated with unacceptable rates of angioedema and, therefore, withdrawn. However, one such agent (omapatrilat) showed promise of NEP/RAS inhibition in treating CKD in animal models, producing greater reductions in proteinuria, glomerulosclerosis and tubulointerstitial fibrosis compared with isolated RAS inhibition. A new class of drug called angiotensin receptor neprilysin inhibitor (ARNi) has been developed. One such drug, LCZ696, has shown substantial benefits in trials in hypertension and HF. In CKD, HF is common due to a range of mechanisms including hypertension and structural heart disease (including left ventricular hypertrophy), suggesting that ARNi could benefit patients with CKD by both retarding the progression of CKD (hence delaying the need for renal replacement therapy) and reducing the risk of cardiovascular disease. LCZ696 is now being studied in a CKD population. |
| first_indexed | 2024-03-07T04:39:05Z |
| format | Journal article |
| id | oxford-uuid:d0fe232a-207d-4572-8461-e1e2c4ad661b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:39:05Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:d0fe232a-207d-4572-8461-e1e2c4ad661b2022-03-27T07:53:54ZNeprilysin inhibition in chronic kidney disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d0fe232a-207d-4572-8461-e1e2c4ad661bEnglishSymplectic Elements at Oxford2014Judge, PHaynes, RLandray, MBaigent, CDespite current practice, patients with chronic kidney disease (CKD) are at increased risk of progression to end-stage renal disease and cardiovascular events. Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. NEPi enhances the activity of natriuretic peptide systems leading to natriuresis, diuresis and inhibition of the renin-angiotensin system (RAS), which could act as a potentially beneficial counter-regulatory system in states of RAS activation such as chronic heart failure (HF) and CKD. Early NEPi drugs were combined with angiotensin-converting enzyme inhibitors but were associated with unacceptable rates of angioedema and, therefore, withdrawn. However, one such agent (omapatrilat) showed promise of NEP/RAS inhibition in treating CKD in animal models, producing greater reductions in proteinuria, glomerulosclerosis and tubulointerstitial fibrosis compared with isolated RAS inhibition. A new class of drug called angiotensin receptor neprilysin inhibitor (ARNi) has been developed. One such drug, LCZ696, has shown substantial benefits in trials in hypertension and HF. In CKD, HF is common due to a range of mechanisms including hypertension and structural heart disease (including left ventricular hypertrophy), suggesting that ARNi could benefit patients with CKD by both retarding the progression of CKD (hence delaying the need for renal replacement therapy) and reducing the risk of cardiovascular disease. LCZ696 is now being studied in a CKD population. |
| spellingShingle | Judge, P Haynes, R Landray, M Baigent, C Neprilysin inhibition in chronic kidney disease. |
| title | Neprilysin inhibition in chronic kidney disease. |
| title_full | Neprilysin inhibition in chronic kidney disease. |
| title_fullStr | Neprilysin inhibition in chronic kidney disease. |
| title_full_unstemmed | Neprilysin inhibition in chronic kidney disease. |
| title_short | Neprilysin inhibition in chronic kidney disease. |
| title_sort | neprilysin inhibition in chronic kidney disease |
| work_keys_str_mv | AT judgep neprilysininhibitioninchronickidneydisease AT haynesr neprilysininhibitioninchronickidneydisease AT landraym neprilysininhibitioninchronickidneydisease AT baigentc neprilysininhibitioninchronickidneydisease |